Issue Date: September 20, 2010
Galapagos Buys GSK R&D Site
GlaxoSmithKline is selling its Zagreb, Croatia, R&D facility to Belgian contract research organization Galapagos. The 130 employees at the site will transfer to Galapagos, which will in turn provide GSK with R&D services worth $18 million over a three-year period. In July, GSK sold its Verona, Italy, R&D center to Aptuit, which agreed to take on the 500 employees at the lab and continue providing R&D services for GSK.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society